Current research endorses the use of GLP-1 RAs in the cardiometabolic management of patients with T2DM, obesity, and high cardiovascular risk, since these agents, in addition to metabolic control, address some of the important pathophysiological drivers of cardiovascular disease. Here, GLP1R is linked to type 2 diabetes mellitus.